CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice

Science Advances

Volumn 3, Issue 4, 2017, Pages

  Zhang, Yu ^a,c   Long, Chengzu ^a,c   Li, Hui ^a   McAnally, John R ^a   Baskin, Kedryn K ^a   Shelton, John M ^b   Bassel Duby, Rhonda ^a   Olson, Eric N ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; GENE THERAPY; MAMMALS; MUSCLE; STEM CELLS;

CARDIOMYOCYTES; DILATED CARDIOMYOPATHY; DUCHENNE MUSCULAR DYSTROPHIES; GENETIC MUTATIONS; INDUCED PLURIPOTENT STEM CELLS; MUSCULAR DYSTROPHY; PATHOPHYSIOLOGICAL; STRIATED MUSCLES;

GENES;

APO-DYSTROPHIN 1; DMD PROTEIN, HUMAN; DYSTROPHIN;

ANIMAL; ANIMAL MUSCULAR DYSTROPHY; CARDIAC MUSCLE CELL; CRISPR CAS SYSTEM; DUCHENNE MUSCULAR DYSTROPHY; GENETICS; HUMAN; METABOLISM; MOUSE; PATHOLOGY; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CRISPR-CAS SYSTEMS; DYSTROPHIN; HUMANS; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOCYTES, CARDIAC;

EID: 85020835403     PISSN: None     EISSN: 23752548     Source Type: Journal    
DOI: 10.1126/sciadv.1602814     Document Type: Article

References (32)

1. K. P. Campbell, S. D. Kahl, Association of dystrophin and an integral membrane glycoprotein. Nature 338, 259–262 (1989).
2. K. Hollinger, J. S. Chamberlain, Viral vector-mediated gene therapies. Curr. Opin. Neurol. 28, 522–527 (2015).
3. B. Bostick, J.-H. Shin, Y. Yue, D. Duan, AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice. Mol. Ther. 19, 1826–1832 (2011).
4. Y. Shimizu-Motohashi, S. Miyatake, H. Komaki, S. Takeda, Y. Aoki, Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: From discovery to clinical trials. Am. J. Transl. Res. 8, 2471–2489 (2016).
5. F. J. M. Mojica, C. Díez-Villaseñor, J. García-Martínez, E. Soria, Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J. Mol. Evol. 60, 174–182 (2005).
6. Y. Wu, D. Liang, Y. Wang, M. Bai, W. Tang, S. Bao, Z. Yan, D. Li, J. Li, Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 13, 659–662 (2013).
7. C. Long, J. R. McAnally, J. M. Shelton, A. A. Mireault, R. Bassel-Duby, E. N. Olson, Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA. Science 345, 1184–1188 (2014).
8. H. Yin, W. Xue, S. Chen, R. L. Bogorad, E. Benedetti, M. Grompe, V. Koteliansky, P. A. Sharp, T. Jacks, D. G. Anderson, Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551–553 (2014).
9. M. Tabebordbar, K. Zhu, J. K. W. Cheng, W. L. Chew, J. J. Widrick, W. X. Yan, C. Maesner, E. Y. Wu, R. Xiao, F. A. Ran, L. Cong, F. Zhang, L. H. Vandenberghe, G. M. Church, A. J. Wagers, In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407–411 (2016).
10. C. E. Nelson, C. H. Hakim, D. G. Ousterout, P. I. Thakore, E. A. Moreb, R. M. Castellanos Rivera, S. Madhavan, X. Pan, F. A. Ran, W. X. Yan, A. Asokan, F. Zhang, D. Duan, C. A. Gersbach, In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403–407 (2016).
11. M. A. DeWitt, W. Magis, N. L. Bray, T. Wang, J. R. Berman, F. Urbinati, S.-J. Heo, T. Mitros, D. P. Muñoz, D. Boffelli, D. B. Kohn, M. C. Walters, D. Carroll, D. I. K. Martin, J. E. Corn, Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci. Transl. Med. 8, 360ra134 (2016).
12. C. Long, L. Amoasii, R. Bassel-Duby, E. N. Olson, Genome editing of monogenic neuromuscular diseases: A systematic review. JAMA Neurol. 73, 1349–1355 (2016).
13. F. A. Ran, L. Cong, W. X. Yan, D. A. Scott, J. S. Gootenberg, A. J. Kriz, B. Zetsche, O. Shalem, X. Wu, K. S. Makarova, E. V. Koonin, P. A. Sharp, F. Zhang, In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015).
14. B. Zetsche, J. S. Gootenberg, O. O. Abudayyeh, I. M. Slaymaker, K. S. Makarova, P. Essletzbichler, S. E. Volz, J. Joung, J. van der Oost, A. Regev, E. V. Koonin, F. Zhang, Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163, 759–771 (2015).
15. Y. Kim, S.-A. Cheong, J. G. Lee, S.-W. Lee, M. S. Lee, I.-J. Baek, Y. H. Sung, Generation of knockout mice by Cpf1-mediated gene targeting. Nat. Biotechnol. 34, 808–810 (2016).
16. D. Kim, J. Kim, J. K. Hur, K. W. Been, S.-H. Yoon, J.-S. Kim, Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. Nat. Biotechnol. 34, 876–881 (2016).
17. S. Q. Tsai, M. S. Prew, N. T. Nguyen, M. M. Welch, J. M. Lopez, Z. R. McCaw, M. J. Aryee, B. P. Kleinstiver, J. K. Joung, Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nat. Biotechnol. 34, 882–887 (2016).
18. E. Tóth, N. Weinhardt, P. Bencsura, K. Huszár, P. I. Kulcsár, A. Tálas, E. Fodor, E. Welker, Cpf1 nucleases demonstrate robust activity to induce DNA modification by exploiting homology directed repair pathways in mammalian cells. Biol. Direct 11, 46 (2016).
19. M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, E. Charpentier, A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).
20. I. Fonfara, H. Richter, M. Bratovič, A. Le Rhun, E. Charpentier, The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. Nature 532, 517–521 (2016).
21. C. Long, L. Amoasii, A. A. Mireault, J. R. McAnally, H. Li, E. Sanchez-Ortiz, S. Bhattacharyya, J. M. Shelton, R. Bassel-Duby, E. N. Olson, Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351, 400–403 (2016).
22. C. S. Young, M. R. Hicks, N. V. Ermolova, H. Nakano, M. Jan, S. Younesi, S. Karumbayaram, C. Kumagai-Cresse, D. Wang, J. A. Zack, D. B. Kohn, A. Nakano, S. F. Nelson, M. C. Miceli, M. J. Spencer, A. D. Pyle, A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell 18, 533–540 (2016).
23. L. Xu, K. H. Park, L. Zhao, J. Xu, M. El Refaey, Y. Gao, H. Zhu, J. Ma, R. Han, CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice. Mol. Ther. 24, 564–569 (2016).
24. A. Aartsma-Rus, I. Fokkema, J. Verschuuren, I. Ginjaar, J. van Deutekom, G.-J. van Ommen, J. T. den Dunnen, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat. 30, 293–299 (2009).
25. S. Cirak, V. Arechavala-Gomeza, M. Guglieri, L. Feng, S. Torelli, K. Anthony, S. Abbs, M. E. Garralda, J. Bourke, D. J. Wells, G. Dickson, M. J. Wood, S. D. Wilton, V. Straub, R. Kole, S. B. Shrewsbury, C. Sewry, J. E. Morgan, K. Bushby, F. Muntoni, Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 378, 595–605 (2011).
26. R. A. Padgett, New connections between splicing and human disease. Trends Genet. 28, 147–154 (2012).
27. P. W. Burridge, E. Matsa, P. Shukla, Z. C. Lin, J. M. Churko, A. D. Ebert, F. Lan, S. Diecke, B. Huber, N. M. Mordwinkin, J. R. Plews, O. J. Abilez, B. Cui, J. D. Gold, J. C. Wu, Chemically defined generation of human cardiomyocytes. Nat. Methods 11, 855–860 (2014).
28. D. P. Millay, M. A. Sargent, H. Osinska, C. P. Baines, E. R. Barton, G. Vuagniaux, H. L. Sweeney, J. Robbins, J. D. Molkentin, Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat. Med. 14, 442–447 (2008).
29. F. Mourkioti, J. Kustan, P. Kraft, J. W. Day, M.-M. Zhao, M. Kost-Alimova, A. Protopopov, R. A. DePinho, D. Bernstein, A. K. Meeker, H. M. Blau, Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy. Nat. Cell Biol. 15, 895–904 (2013).
30. M. Maresca, V. G. Lin, N. Guo, Y. Yang, Obligate ligation-gated recombination (ObLiGaRe): Custom-designed nuclease-mediated targeted integration through nonhomologous end joining. Genome Res. 23, 539–546 (2013).
31. C. Zechner, L. Lai, J. F. Zechner, T. Geng, Z. Yan, J. W. Rumsey, D. Collia, Z. Chen, D. F. Wozniak, T. C. Leone, D. P. Kelly, Total skeletal muscle PGC-1 deficiency uncouples mitochondrial derangements from fiber type determination and insulin sensitivity. Cell Metab. 12, 633–642 (2010).
32. K. K. Baskin, C. E. Grueter, C. M. Kusminski, W. L. Holland, A. L. Bookout, S. Satapati, Y. M. Kong, S. C. Burgess, C. R. Malloy, P. E. Scherer, C. B. Newgard, R. Bassel-Duby, E. N. Olson, MED13-dependent signaling from the heart confers leanness by enhancing metabolism in adipose tissue and liver. EMBO Mol. Med. 6, 1610–1621 (2014).